Kvartalsrapport (Q2)
3 dager siden‧38min
Ordredybde
Antall
Kjøp
0
Selg
Antall
0
Siste handler
| Tid | Pris | Antall | Kjøpere | Selger |
|---|---|---|---|---|
| - | - | - | - |
Høy
17,2VWAP
Lav
14,73OmsetningAntall
13,1 804 068
VWAP
Høy
17,2Lav
14,73OmsetningAntall
13,1 804 068
Meglerstatistikk
Fant ingen data
Selskapshendelser
| Kommende | |
|---|---|
Selskapskalender ikke tilgjengelig | |
| Historisk | ||
|---|---|---|
| 2025 Kvartalsrapport (Q2) | 7. aug. | |
| 2025 Generalforsamling | 10. juni | |
| 2025 Kvartalsrapport (Q1) | 13. mai | |
| 2024 Kvartalsrapport (Q4) | 18. mars | |
| 2024 Årsrapport | 18. mars |
Data hentes fra Morningstar, Quartr
Kunder besøkte også
Shareville
Bli med i samtalen på SharevilleEt fellesskap av investorer som deler innsikt og kunnskap i sine porteføljer.
Logg inn
for 2 døgn siden·Virker til at de har turnert i den: «Produktsalg på 18,9 millioner dollar i andre kvartal 2025, som representerer en vekst på 108 % sammenlignet med andre kvartal 2024 og det 18. kvartalet på rad med sekvensiell produktsalgsvekst» «Selskapet anslår at det vil nå en årlig omsetningsrate på 80 millioner dollar i tredje kvartal, ett kvartal foran tidligere prognoser»
31. jan. 2022 · Endret31. jan. 2022 · Endrethttps://www.nasdaq.com/articles/eton-pharmaceuticals%3A-following-fda-approval-this-5-star-analyst-says-buy-2020-09-30 Eton Pharmaceuticals: Following FDA Approval, This 5-Star Analyst Says ‘Buy’ CONTRIBUTOR Maya Sasson TipRanks PUBLISHED SEP 30, 2020 6:57PM EDT A green light from the FDA can change everything for a healthcare company. This might just be the case for Eton Pharmaceuticals (ETON). On September 29, the company announced that the FDA had given Alkindi Sprinkle, its taste-neutral sprinkle (granule) formulation of hydrocortisone designed as a replacement therapy for pediatric adrenal insufficiency (AI), its stamp of approval. The verdict came on the previously scheduled PDUFA date. Additionally, six clinical studies, including the first and only interventional Phase 3 study of oral hydrocortisone for pediatric AI in neonates to children under eight years of age, served as the basis for the approval. Before the therapy got the FDA approval, oral hydrocortisone was only approved in tablet formulations of 5mg and stronger, with many pediatric patients requiring significantly lower doses. Alkindi Sprinkle will be available in 0.5mg, 1mg, 2mg and 5mg strengths, which will give clinicians flexibility to individualize dosing based on each patient’s needs in accordance with the instructions for dosage and administration. Weighing in on the development for H.C. Wainwright, 5-star analyst Raghuram Selvaraju stated, “In our view, the drug could be launched with a very small, targeted sales effort and may generate peak sales of $57 million by 2026. This is the third agent from Eton's pipeline to receive regulatory approval —after Biorphen in October 2019 and Alaway a few days ago—and this ought to be viewed as further validation of Eton's pharmaceutical product development capabilities.” According to management, the product could be commercially available in Q4 2020. That being said, the rest of its pipeline could also serve as significant upside drivers, in Selvaraju’s opinion. Everything that ETON has going for it convinced Selvaraju to keep a Buy rating on the stock. Along with the call, he bumped up the price target from $18 to $20, suggesting 153% upside potential. (To watch Selvaraju’s track record, click here) Turning now to the rest of the Street, other analysts agree with Selvaraju. 3 Buys and no Holds or Sells translate to a Strong Buy consensus rating. At $15.67, the average price target implies 100% upside potential. (See ETON stock analysis on TipRanks) To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
Kommentarene ovenfor kommer fra brukere på Nordnets sosiale nettverk Shareville og er verken redigert eller forhåndsvist av Nordnet. De innebærer ikke at Nordnet gir investeringsråd eller investeringsanbefalinger. Nordnet påtar seg ikke ansvar for kommentarene.
Nyheter og Analyser
Det er for øyeblikket ingen nyheter
Nyheter og/eller generelle investeringsanbefalinger, eller utdrag av disse på denne siden og øvrige lenker, er produsert og levert av den spesifiserte leverandøren. Nordnet har ikke deltatt i utarbeidelsen, og har ikke gjennomgått eller gjort endringer i materialet. Les mer om investeringsanbefalinger.
Kvartalsrapport (Q2)
3 dager siden‧38min
Nyheter og Analyser
Det er for øyeblikket ingen nyheter
Nyheter og/eller generelle investeringsanbefalinger, eller utdrag av disse på denne siden og øvrige lenker, er produsert og levert av den spesifiserte leverandøren. Nordnet har ikke deltatt i utarbeidelsen, og har ikke gjennomgått eller gjort endringer i materialet. Les mer om investeringsanbefalinger.
Shareville
Bli med i samtalen på SharevilleEt fellesskap av investorer som deler innsikt og kunnskap i sine porteføljer.
Logg inn
- for 2 døgn siden·Virker til at de har turnert i den: «Produktsalg på 18,9 millioner dollar i andre kvartal 2025, som representerer en vekst på 108 % sammenlignet med andre kvartal 2024 og det 18. kvartalet på rad med sekvensiell produktsalgsvekst» «Selskapet anslår at det vil nå en årlig omsetningsrate på 80 millioner dollar i tredje kvartal, ett kvartal foran tidligere prognoser»
- 31. jan. 2022 · Endret31. jan. 2022 · Endrethttps://www.nasdaq.com/articles/eton-pharmaceuticals%3A-following-fda-approval-this-5-star-analyst-says-buy-2020-09-30 Eton Pharmaceuticals: Following FDA Approval, This 5-Star Analyst Says ‘Buy’ CONTRIBUTOR Maya Sasson TipRanks PUBLISHED SEP 30, 2020 6:57PM EDT A green light from the FDA can change everything for a healthcare company. This might just be the case for Eton Pharmaceuticals (ETON). On September 29, the company announced that the FDA had given Alkindi Sprinkle, its taste-neutral sprinkle (granule) formulation of hydrocortisone designed as a replacement therapy for pediatric adrenal insufficiency (AI), its stamp of approval. The verdict came on the previously scheduled PDUFA date. Additionally, six clinical studies, including the first and only interventional Phase 3 study of oral hydrocortisone for pediatric AI in neonates to children under eight years of age, served as the basis for the approval. Before the therapy got the FDA approval, oral hydrocortisone was only approved in tablet formulations of 5mg and stronger, with many pediatric patients requiring significantly lower doses. Alkindi Sprinkle will be available in 0.5mg, 1mg, 2mg and 5mg strengths, which will give clinicians flexibility to individualize dosing based on each patient’s needs in accordance with the instructions for dosage and administration. Weighing in on the development for H.C. Wainwright, 5-star analyst Raghuram Selvaraju stated, “In our view, the drug could be launched with a very small, targeted sales effort and may generate peak sales of $57 million by 2026. This is the third agent from Eton's pipeline to receive regulatory approval —after Biorphen in October 2019 and Alaway a few days ago—and this ought to be viewed as further validation of Eton's pharmaceutical product development capabilities.” According to management, the product could be commercially available in Q4 2020. That being said, the rest of its pipeline could also serve as significant upside drivers, in Selvaraju’s opinion. Everything that ETON has going for it convinced Selvaraju to keep a Buy rating on the stock. Along with the call, he bumped up the price target from $18 to $20, suggesting 153% upside potential. (To watch Selvaraju’s track record, click here) Turning now to the rest of the Street, other analysts agree with Selvaraju. 3 Buys and no Holds or Sells translate to a Strong Buy consensus rating. At $15.67, the average price target implies 100% upside potential. (See ETON stock analysis on TipRanks) To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
Kommentarene ovenfor kommer fra brukere på Nordnets sosiale nettverk Shareville og er verken redigert eller forhåndsvist av Nordnet. De innebærer ikke at Nordnet gir investeringsråd eller investeringsanbefalinger. Nordnet påtar seg ikke ansvar for kommentarene.
Ordredybde
Antall
Kjøp
0
Selg
Antall
0
Siste handler
| Tid | Pris | Antall | Kjøpere | Selger |
|---|---|---|---|---|
| - | - | - | - |
Høy
17,2VWAP
Lav
14,73OmsetningAntall
13,1 804 068
VWAP
Høy
17,2Lav
14,73OmsetningAntall
13,1 804 068
Meglerstatistikk
Fant ingen data
Kunder besøkte også
Selskapshendelser
| Kommende | |
|---|---|
Selskapskalender ikke tilgjengelig | |
| Historisk | ||
|---|---|---|
| 2025 Kvartalsrapport (Q2) | 7. aug. | |
| 2025 Generalforsamling | 10. juni | |
| 2025 Kvartalsrapport (Q1) | 13. mai | |
| 2024 Kvartalsrapport (Q4) | 18. mars | |
| 2024 Årsrapport | 18. mars |
Data hentes fra Morningstar, Quartr
Kvartalsrapport (Q2)
3 dager siden‧38min
Nyheter og Analyser
Det er for øyeblikket ingen nyheter
Nyheter og/eller generelle investeringsanbefalinger, eller utdrag av disse på denne siden og øvrige lenker, er produsert og levert av den spesifiserte leverandøren. Nordnet har ikke deltatt i utarbeidelsen, og har ikke gjennomgått eller gjort endringer i materialet. Les mer om investeringsanbefalinger.
Selskapshendelser
| Kommende | |
|---|---|
Selskapskalender ikke tilgjengelig | |
| Historisk | ||
|---|---|---|
| 2025 Kvartalsrapport (Q2) | 7. aug. | |
| 2025 Generalforsamling | 10. juni | |
| 2025 Kvartalsrapport (Q1) | 13. mai | |
| 2024 Kvartalsrapport (Q4) | 18. mars | |
| 2024 Årsrapport | 18. mars |
Data hentes fra Morningstar, Quartr
Shareville
Bli med i samtalen på SharevilleEt fellesskap av investorer som deler innsikt og kunnskap i sine porteføljer.
Logg inn
- for 2 døgn siden·Virker til at de har turnert i den: «Produktsalg på 18,9 millioner dollar i andre kvartal 2025, som representerer en vekst på 108 % sammenlignet med andre kvartal 2024 og det 18. kvartalet på rad med sekvensiell produktsalgsvekst» «Selskapet anslår at det vil nå en årlig omsetningsrate på 80 millioner dollar i tredje kvartal, ett kvartal foran tidligere prognoser»
- 31. jan. 2022 · Endret31. jan. 2022 · Endrethttps://www.nasdaq.com/articles/eton-pharmaceuticals%3A-following-fda-approval-this-5-star-analyst-says-buy-2020-09-30 Eton Pharmaceuticals: Following FDA Approval, This 5-Star Analyst Says ‘Buy’ CONTRIBUTOR Maya Sasson TipRanks PUBLISHED SEP 30, 2020 6:57PM EDT A green light from the FDA can change everything for a healthcare company. This might just be the case for Eton Pharmaceuticals (ETON). On September 29, the company announced that the FDA had given Alkindi Sprinkle, its taste-neutral sprinkle (granule) formulation of hydrocortisone designed as a replacement therapy for pediatric adrenal insufficiency (AI), its stamp of approval. The verdict came on the previously scheduled PDUFA date. Additionally, six clinical studies, including the first and only interventional Phase 3 study of oral hydrocortisone for pediatric AI in neonates to children under eight years of age, served as the basis for the approval. Before the therapy got the FDA approval, oral hydrocortisone was only approved in tablet formulations of 5mg and stronger, with many pediatric patients requiring significantly lower doses. Alkindi Sprinkle will be available in 0.5mg, 1mg, 2mg and 5mg strengths, which will give clinicians flexibility to individualize dosing based on each patient’s needs in accordance with the instructions for dosage and administration. Weighing in on the development for H.C. Wainwright, 5-star analyst Raghuram Selvaraju stated, “In our view, the drug could be launched with a very small, targeted sales effort and may generate peak sales of $57 million by 2026. This is the third agent from Eton's pipeline to receive regulatory approval —after Biorphen in October 2019 and Alaway a few days ago—and this ought to be viewed as further validation of Eton's pharmaceutical product development capabilities.” According to management, the product could be commercially available in Q4 2020. That being said, the rest of its pipeline could also serve as significant upside drivers, in Selvaraju’s opinion. Everything that ETON has going for it convinced Selvaraju to keep a Buy rating on the stock. Along with the call, he bumped up the price target from $18 to $20, suggesting 153% upside potential. (To watch Selvaraju’s track record, click here) Turning now to the rest of the Street, other analysts agree with Selvaraju. 3 Buys and no Holds or Sells translate to a Strong Buy consensus rating. At $15.67, the average price target implies 100% upside potential. (See ETON stock analysis on TipRanks) To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
Kommentarene ovenfor kommer fra brukere på Nordnets sosiale nettverk Shareville og er verken redigert eller forhåndsvist av Nordnet. De innebærer ikke at Nordnet gir investeringsråd eller investeringsanbefalinger. Nordnet påtar seg ikke ansvar for kommentarene.
Ordredybde
Antall
Kjøp
0
Selg
Antall
0
Siste handler
| Tid | Pris | Antall | Kjøpere | Selger |
|---|---|---|---|---|
| - | - | - | - |
Høy
17,2VWAP
Lav
14,73OmsetningAntall
13,1 804 068
VWAP
Høy
17,2Lav
14,73OmsetningAntall
13,1 804 068
Meglerstatistikk
Fant ingen data